4 Analysts Have This To Say About Twist Bioscience
Portfolio Pulse from Benzinga Insights
Twist Bioscience (NASDAQ:TWST) received mixed analyst ratings with a notable increase in its 12-month price target to $44.5, up 61.82% from $27.50. Analysts from Scotiabank, Barclays, and Goldman Sachs raised their price targets, reflecting optimism about the company's disruptive DNA synthesis platform and its financial performance, including a 16.82% revenue growth rate and strong profitability metrics despite a negative net margin.
February 05, 2024 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Twist Bioscience's stock may see short-term positive movement due to upgraded analyst ratings and a significant increase in its 12-month price target, reflecting confidence in its technology and financial growth.
The positive adjustment in analyst ratings and the substantial increase in the price target for Twist Bioscience are indicative of a bullish outlook on the company's future performance. This optimism is rooted in the company's disruptive DNA synthesis technology and its recent financial achievements, including a significant revenue growth rate. These factors are likely to contribute to positive investor sentiment and potential short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100